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Background: Recurrent miscarriage is generally defined as three or more miscarriages before gestational week 20.
Recurrent miscarriage affects 1% of all women and the condition can only be explained by parental chromosome
abnormalities, uterine malformations, or endocrine or thrombophilic disturbances to a limited extent. Immunological
disturbances are hypothesised to play an important role in recurrent miscarriage and, therefore, various types of
immunologically-based therapies have been tested in recurrent miscarriage patients including intravenous
immunoglobulins. So far, at least eight randomised placebo-controlled trials, with opposing results, investigating
intravenous immunoglobulins with a total of 324 recurrent miscarriage patients have been published.
Methods/Design: We will include randomised clinical trials irrespective of publication date, publication type,
publication language, and publication status investigating infusions with immunoglobulins in relation to pregnancy
compared to placebo, no intervention, or treatment as usual for assessments of benefits and harms. The relevant
published literature will be searched using the following databases: Cochrane Central Register of Controlled Trials,
Medline, Embase, WHO International Clinical Trials Registry Platform, and Ovid Medline In-Process and Other
Non-Indexed Citations databases. Two review authors will independently extract data and assess risk of bias. We
will undertake meta-analyses according to the recommendations stated in the Cochrane Handbook for Systematic
Reviews of Interventions. Further, we will conduct trial sequential analyses and individual patient data meta-analyses.
(Continued on next page)* Correspondence: piaegerup@hotmail.com
1The Fertility Department, Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark
2Copenhagen Trial Unit, Centre for Clinical Intervention Research,
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
© 2014 Egerup et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Egerup et al. Systematic Reviews 2014, 3:89 Page 2 of 8
http://www.systematicreviewsjournal.com/content/3/1/89(Continued from previous page)
Discussion: A miscarriage results in great sorrow, loss of life quality, and personal concern. In particular, recurrent
miscarriage is extremely stressful and burdensome. It is, therefore, very important to conduct research in this area.
There is currently no evidence-based treatment for women with recurrent miscarriage which significantly improves
their ability to give live birth. Therefore, a comprehensive up-to-date systematic review is needed. By using individual
patient data, it will be possible to provide new knowledge about the benefits and harms of intravenous
immunoglobulins and try to identify the subgroup in which the treatment will have the highest impact.
This systematic review protocol was registered within the International Prospective Register of Systematic Reviews
(PROSPERO) as number CRD42014007112.
Keywords: Systematic review, Meta-analysis, Recurrent miscarriage, Immunotherapy, ImmunoglobulinsBackground
Recurrent miscarriage (RM) is generally defined as three or
more miscarriages before gestational week 20 [1]. However,
many clinicians define RM as two or more miscarriages [2].
Primary RM refers to a series of miscarriages without a pre-
vious live birth. Secondary RM refers to a woman with a
series of miscarriages subsequent to a previous live birth
[1]. In some clinics it is called secondary RM if the miscar-
riage has been preceded by a live birth or stillbirth after
gestational week 22 [3]. RM affects 1% of all women and
only in a minority can the condition be explained by par-
ental chromosome abnormalities, uterine malformations,
or endocrine or thrombophilic disturbances [1].
Immunological disturbances are hypothesised to play
an important role in RM. Elevated levels of natural killer
cell subset, autoantibodies, and inflammatory cytokines
can be found in the peripheral blood of these patients
and significantly more activated leukocytes and abnor-
mal levels of specific natural killer cell subsets in the de-
cidua of women with RM have also been described [4-7].
There is some evidence that immunological disturbances
play a larger role in secondary RM compared to primary
RM. There is a higher prevalence of the immunological
high responder HLA allele HLA-DR3 and specific HLA-
G genotypes in secondary RM than in primary RM and
controls without RM [7,8]. A study also shows that there
is an excess of boys born prior to secondary RM and an
excess of live born girls in women giving birth after
secondary RM compared to the expected 1:1 sex ratio
[9]. This gives rise to the hypothesis that women with
RM have developed a harmful immunological reaction
against male-specific minor histocompatibility antigens
(HY-antigens) on the foetus or trophoblast, and that
this results in subsequent increased miscarriage rate of
male conceptions [9].
Because of the association between these immunological
biomarkers and RM, various types of immunologically-
based therapies have been tested in RM patients. Until
now, four different kinds of immunotherapy have been
tested in placebo-controlled trials: prednisone, immunisa-
tion with trophoblast membrane, active immunisation withallogeneic lymphocytes from the partner or donors, and
intravenous immunoglobulins (IvIg) [10-12].
IvIg have several effects like suppression and neutralisa-
tion of autoantibodies, attenuation of natural killer cells, in-
hibition of complement binding, modification of cytokine
production, and expansion of regulatory T lymphocytes
[13-15]. IvIg exhibit a documented effect in many disorders
caused by immunological abnormalities [16]. IvIg are made
by extracting the IgG fractions from plasma from normal
blood donors and, therefore, there are potential risks of
adverse events like allergy and transmission of infections
(for example, HIV, hepatitis, prions). In general, IvIg are
well tolerated, and the most frequent adverse reactions,
which include headache, fever and nausea, occur in less
than 5% of patients [13].
So far, at least eight randomised placebo-controlled trials
investigating IvIg with a total of 324 RM patients have been
published, with conflicting results [12,17-23]. Among these,
one found a statistically significant beneficial effect [17],
one found a strong trend towards a beneficial effect [18]
and six showed no effects [12,19-23].
These differences can in theory be explained by the
fact that the trials conducted so far are very heterogeneous
with regard to the selection of patients, doses of IvIg, and
starting time of infusions. The doses used in the trials range
from small doses [17,20,22] to doses similar to those used
in the treatment of autoimmune diseases [12]. There are
also large variations in the starting time for the first infu-
sion and the number of infusions administered in the trials.
The patient population differs much in the different trials,
especially by numbers of miscarriages and the participation
of primary or secondary RM patients. This heterogeneity
may blur a possible treatment effect.
There is, in our view, an urgent need for an up-dated
systematic review with meta-analysis and trial sequential
analyses of randomised trials of IvIg in RM. One reason is
that there is a need to conduct important subgroup ana-
lyses to evaluate in which subgroup the treatment may be
most beneficial. We will, in our systematic review, include
data from the newest randomised placebo-controlled trial,
Trial of the Efficacy of Intravenous Immunoglobulin for
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Miscarriage (ClinicalTrials.gov Identifier: NCT00722475),
which is expected to be published in 2014.Methods
Types of participants
Women who meet the following inclusion criteria will
be included:
1) A history of two or more consecutive miscarriages,
defined according to the trialists
2) Normal anatomy of the uterine cavity assessed by,
for example, hysterosalpingogram, sonohysterogram,
vaginal sonography, or hysteroscopy
3) Normal parental karyotypes
4) Pregnancy diagnosed by positive beta-human
chorionic gonadotropin (β-hCG) test in serum, or
urine, or by ultrasound
5) Informed consent for participation in the
randomised trialTypes of interventions
Experimental groups
IvIg initiated before pregnancy or during the first tri-
mester of pregnancy regardless of dose or length of
intervention period.Control groups
Placebo: any placebo substance containing no active
substance.
No intervention.
Treatment as usual: usual treatment or care, as defined
by the trialists.Co-interventions
We will allow all types of co-interventions as long as
they are given equally in both intervention groups.Types of studies
We will include randomised clinical trials irrespective of
publication date, publication type, publication language,
and publication status investigating infusions with IvIg
in relation to pregnancy compared with placebo, no
intervention, or treatment as usual for assessments of
benefits and harms. For assessments of harms we will
also include the quasi-randomised clinical studies and
observational studies that we happen to identify in our
search for randomised clinical trials.
We will use individual patient data (IPD) combined with
aggregate data (AD) in the data analyses in order to detect
a subgroup of patients with most beneficial effect.Outcomes
Primary outcomes
The primary outcomes are:
1) The proportion of women not giving live birth,
defined according to the trialists
2) The proportion of women experiencing a serious
adverse event (SAE) defined as any adverse event
that results in death, is life-threatening, requires
hospitalisation or prolongation of existing
hospitalisation, or results in persistent or significant
disability or incapacity [24]. SAE will be assessed as
a composite of all the above events
3) The proportion of live-born babies experiencing a
SAE defined as any adverse event that results in
death, is life-threatening, requires hospitalisation in
a neonatal care unit or prolongation of existing
hospitalisation, results in persistent or significant
disability or incapacity or is a congenital anomaly or
birth defect [24]. SAE will be assessed as a
composite of all the above events
Secondary outcomes
The secondary outcomes for all women are:
1) The proportion of women experiencing an adverse
event (AE) defined as any undesirable medical event
occurring to a participant during a clinical trial,
which does not necessarily have a causal relationship
with the intervention [24]. AE will be assessed as a
composite of all the above events
2) The women’s quality of life, as defined by the trialists
The secondary outcomes for women with a live birth
and their babies are:
1) Proportion of women who gives live birth
prematurely (<37 weeks)
2) Sex of the baby
3) The proportion of babies with low birth weight, that
is < 2,500 g
4) The proportion of babies experiencing an AE. AE
will be assessed as a composite
5) The babies’ quality of life, as defined by the trialists
Searches
The relevant published literature will be searched using
the following databases: the Cochrane Central Register of
Controlled Trials (Central 2014), Medline (1950 to April
2014), Embase (1947 to April 2014), WHO International
Clinical Trials Registry Platform (April 2014), and Ovid
Medline In-Process and Other Non-Indexed Citations
databases (April 2014). The following medical subject
headings (MeSH) terms, keywords and their combinations
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apy; foetal death, abortion; habitual abortion; spontaneous;
foetal loss; miscarriage; recurrent abortion; recurrent
miscarriage. Appropriate suffixes will be used for each
database. The Cochrane strategy for identifying ran-
domised trials using the relevant MeSH terms and
keywords will be used. Similar search strategies will be
used in Central, Embase and Ovid Medline In-Process
and other non-indexed citation databases. Relevant
abstracts from the annual meetings of American and
European Societies of Reproductive Medicine and Human
Reproduction will be searched. The reference lists of
the identified reports will be manually searched for
other relevant publications.
No language restrictions will be applied.
Selection of trials
Two authors (PE and JL) will independently identify
trials for inclusion. Firstly, titles and abstracts of the
records retrieved by the search will be assessed in
order to exclude those that are irrelevant. For the
remaining records, full-text articles will be retrieved
in order to select trials that meet the inclusion cri-
teria. We will list the trials excluded from the second
round and give the reasons for their exclusion. Differ-
ences of opinion will be resolved by discussion with a
third author (CG).
Data extraction
Two authors (PE and JL) will independently extract data
from all included trials. Any disagreement will be dis-
cussed, a third author (CG) will help clarify issues, and
these final decisions will be documented. Data presented
only in graphs and figures will be extracted whenever
possible, but will only be included if two reviewers inde-
pendently had the same result. Authors of trials may be
contacted for clarification.
The following data will be extracted from each of the
eligible included trials:
1) Demographic data (country, trial period, number of
women randomised, age, exact number of previous
miscarriages, primary or secondary RM, levels of
IgG anticardiolipin and positivity/negativity for lupus
anticoagulant)
2) Design and risk of bias (allocation sequence,
allocation concealment, blinding of participants and
treatment providers, blinding of outcome assessors,
incomplete outcome data, selective outcome
reporting, for-profit bias, other sources of bias)
3) Procedural (brand of IvIg, dose and number of
infusions, time of first infusion, type of control
intervention, co-interventions), and
4) Outcome data (see Outcome section)When relevant data are not provided in the eligible
publications, attempts will be made to obtain them by
contacting the original authors.
The original authors will also be contacted with the aim
of collecting individual patient data (IPD). The original
authors will be invited to become part of the ImmuReM
(Intravenous Immunoglobulins in Recurrent Miscarriage)
IPD Study Group, which will co-author the systematic
review publication.
We will aim to obtain the following IPD:
Participant-level information before trial entry:
1) Unique identification coded for anonymity
2) Maternal age at inclusion
3) Exact number of previous miscarriages as defined by
the authors
4) Primary or secondary RM as defined by the authors
5) Levels of IgG anticardiolipin and positivity/negativity
for lupus anticoagulant as defined by the authors
Participant-level information: maternal outcomes after
trial entry:
1) Allocated intervention group (for example, IvIg,
placebo, no intervention)
2) Time of first infusion (for example, before pregnancy
or gestational week in pregnancy)
3) Dose and number of infusions
4) Pregnancy outcome (for example, miscarriage, live
birth, ectopic pregnancy, induced abortion, stillbirth)
5) Time of pregnancy loss/live birth (gestational age)
6) SAEs
7) AEs
8) Quality of life
Participant-level information: infant outcomes:





6) Quality of life
Risk of bias (quality) assessment
We will use the instructions in the Cochrane Handbook
for Systematic Reviews of Interventions [25] and The
Cochrane Hepato-Biliary Group Module [26] in our
evaluation of the methodology and hence bias risk of
the included trials [27-32]. Again, two review authors
(PE and JL) will assess the included trials independently of
each other. We will evaluate the methodology in respect of
generation of allocation sequence, allocation concealment,
blinding of participants and treatment providers, blinding
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outcome reporting, for-profit bias, and other bias sources.
This is done because these components enable classifica-
tion of randomised trials with low risk of bias and high risk
of bias. The latter trials overestimate positive intervention
effects and underestimate negative effects.
We will classify the trials according to the components
below:
Generation of allocation sequence
‘Low risk of bias’: if the allocation sequence is generated
using a computer or a ‘random number table’.
‘Uncertain’: if the procedure in respect of randomisation
is not well described.
‘High risk of bias’: if the trial uses, for example, alternation
for allocating of participants.
Allocation concealment
‘Low risk of bias’: if the allocation sequence is concealed
from the investigators, treatment providers and participants,
for example by central randomisation, and this procedure is
described and documented.
‘Uncertain’: if the procedure to conceal allocation is
not sufficiently described.
‘High risk of bias’: if the investigators, treatment pro-
viders and the participants are able to predict the allo-
cation sequence.
Blinding of the participants and treatment providers
‘Low risk of bias’: if the participants and the treatment
providers are blinded to treatment allocation and this is
described. The placebo infusions should be identical to
the immunoglobulin infusions regarding appearance,
colour and solubility.
‘Uncertain’: if the procedure of blinding is insufficiently
described.
‘High risk of bias’: if blinding is not performed or the
trial uses ‘no intervention’ as control intervention.
Blinding of outcome assessors
‘Low risk of bias’: if the trial investigators performing
the outcome assessments are blinded to the treatment
allocation and this is described.
‘Uncertain’: if the procedure of blinding is insufficiently
described.
‘High risk of bias’: if blinding is not performed.
Incomplete outcome data
‘Low risk of bias’: if dropouts following randomisation can
be described as being similar in the two intervention groups,
and if the trial allows intention-to-treat analysis using
proper methodology, for example, multiple imputations.
‘Uncertain’: if dropouts are not stated, or if the reasons
why the participants dropped out are unclear.‘High risk of bias’: if the pattern of dropouts can be
described as being different in the two intervention
groups.
Selective outcome reporting
‘Low risk of bias’: if all outcomes are stated in the re-
sults, and the hierarchy of the outcomes are documented
in a protocol before launch of randomisation.
‘Uncertain’: if the method of choosing outcomes is in-
adequately described.
‘High risk of bias’: if there is incongruence between the
original protocol and the outcome measures used in the
results, or if not all of the outcome measures are stated.
For-profit bias
‘Low risk of bias’: if the trial is not financed by a com-
pany that might have an interest in a given result.
‘Uncertain’: if there is no description of how the trial is
financed.
‘High risk of bias’: if the trial is financed by a company
that might have an interest in a given result.
Other sources of bias
If other sources of bias are evident these sources of bias
will be presented and the implications will be discussed
and considered in the assessment of treatment effects.
Overall assessment of risk of bias
A trial will be classified as ‘low risk of bias’ only if all of
the bias components described in the above paragraphs
are classified as ‘low risk of bias’. If one or more of the
bias components are classified as ‘uncertain’ or ‘high risk
of bias’ the trial will be classified as ‘high risk of bias’.
In case that we find no trials with low risk of bias or
only find very few trials with low risk of bias, we plan to
identify a group of trials with ‘lower risk of bias’ defined
as those having low risk of bias in the domains: gener-
ation of allocation sequence, allocation concealment,
and blinding of the participants and treatment providers.
Assessment of reporting bias
Different types of reporting biases (for example, publication
bias, time lag bias, outcome reporting bias, and so on)
will be handled following the recommendations of the
Cochrane Handbook for Systematic Reviews of Interventions
[25]. On all outcomes, we will test for funnel plot
asymmetry when there are at least ten trials included
in the meta-analysis. For continuous outcomes with
intervention effects measured as mean difference, the
test proposed by Egger et al. will be used for test for
funnel plot asymmetry [33]. We will take into account
that asymmetric funnel plots are not necessarily caused
by population bias, and publication bias does not ne-
cessarily cause asymmetry in a funnel plot.
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By using IPD we avoid the potential biases of the published
aggregate data (AD) as we can use consistent inclusion/
exclusion criteria across the included randomised clinical
trials. One potential problem for IPD analyses is that IPD
may not be available from all the trials and results from an
IPD-only meta-analysis may be biased if unavailability of
IPD is related to the trial results. To avoid the bias we will
supplement the available IPD with AD for those studies
where IPD are not available.
Strategy for data synthesis
We will undertake meta-analyses according to the rec-
ommendations stated in the Cochrane Handbook for
Systematic Reviews of Interventions [25]. For binary
outcomes we will calculate a standard estimation of
the risk ratio (RR) and its 95% confidence interval (CI).
For continuous outcomes we will estimate the mean dif-
ference (MD) between groups. We prefer not to calculate
effect size measures (standardized mean difference, SMD).
However, if scales of very considerable similarity are used,
we can presume there is a small difference in the different
measurements, we will calculate effect size and transform
the effect back to the units of one or more of the specific
instruments. All meta-analyses will be performed both
with a fixed-effect and a random-effects model.
We will also perform trial sequential analyses on the
outcomes, in order to control the risks of type I and type
II errors that occur in traditional meta-analyses due to
sparse data and repetitive analyses of accumulating
[34-39]. In order to control these risks we will calculate
the diversity-adjusted required information size and
assess the eventual breach of the cumulative Z-curve
of the relevant trial sequential monitoring boundaries.
A more detailed description of trial sequential analysis
can be found at http://www.ctu.dk/tsa/. For binary out-
comes we will estimate the diversity adjusted required
information size based on the proportion of patients
with an outcome in the control group, a risk ratio of
20% or as suggested by the trials with low risk of bias,
an α of 5%, a β of 20%, and diversity of 30% and 60%,
or as suggested by the trials in the meta-analysis. For
continuous outcomes we will estimate the diversity-
adjusted required information size based on the standard
deviation (SD) observed in the control group of trials with
low risk of bias and a minimal relevant difference of 50%
of this standard deviation, an α of 5%, a β of 20%, and di-
versity of 30% and 60%, or as suggested by the trials in the
meta-analysis.
For all outcomes and according to availability we will
combine IPD and published AD into a pooled effect
measure using Riley’s two stage method [40]. In the two-
stage method the available IPD are first reduced to AD
in each trial and these AD (from the IPD studies) arecombined with the existing AD (from the AD trials) using
standard meta-analyses AD techniques. All meta-analyses
will be performed both with a fixed-effect and a random-
effects model.Dealing with missing data
Dichotomous data
For dichotomous outcomes, we will analyse data according
to the intention-to-treat principles, whereby all participants
randomised in each trial are included in the analyses.
Participants with missing outcome data will initially
be considered as having: 1) no live birth; 2) no SAEs
(for the women); and 3) no AEs (for the women).
For women with live birth, we will, in the primary ana-
lyses, impute missing values assuming that the participants
missing at follow-up had: 1) no SAEs (for the babies); 2) no
premature birth; 3) equal number of live born boys and
girls; 4) no low birth weight; and 5) no AEs (for the babies).Continuous data
If SDs are not reported they will be calculated if this is
possible using other data from the trial. If calculation is
impossible, the SDs will be imputed from trials with
similar characteristics.Sensitivity analyses
Assumption for lost dichotomous data
We will perform three sensitivity analyses:
1) ‘Best-worst-case’ scenario: It will be assumed that all
women lost to follow-up in the experimental group
had no outcome and all women lost to follow-up in
the control group had the outcome.
2) ‘Worst-best-case’ scenario: It will be assumed that all
women lost to follow-up in the experimental group
had the outcome and all women lost to follow-up in
the control group had no outcome.
3) Per-protocol analysis: We will analyse the outcomes
after exclusion of women with 1) ectopic
pregnancies; 2) miscarriages with a chromosome
abnormal foetus; 3) genetic termination and 4)
women, who did not complete the intervention as
defined by the authors.Assumptions for lost continuous data
Where assumptions have to be made regarding missing
SDs (see: Dealing with missing data), sensitivity analysis
will be undertaken testing how prone results are to change
when 'completer' data only are compared to the imputed
data using the above assumption. If there is a substantial
difference, we will report results and discuss them but
continue to employ our assumption.
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If the necessary data are available, the following subgroup
analyses will be conducted:
1) Trials with ‘low risk of bias’ compared to trials with
‘high risk of bias’, or if we find no trials with ‘low risk
of bias’, we will compare trials with ‘lower risk of
bias’ to trials with ‘high risk of bias’
2) Participants with ≥ three miscarriages compared to
participants with fewer miscarriages
3) Participants with ≥ four miscarriages compared to
participants with fewer miscarriages
4) Participants with secondary RM compared to
participants with primary RM
5) Trials providing doses of IvIg ≥ the median dose in
grams in all trials from before conception to
gestational week 10 in all trials compared to trials
providing IvIg doses < median
6) Patients without lupus anticoagulant and/or IgG
anticardiolipin as defined by the authors compared
to patients with lupus anticoagulant and/or IgG
anticardiolipin as defined by the authors
Discussion
A great mental strain is imposed on a woman if she is not
being able to give live birth. Thus, a miscarriage results in
great sorrow, loss of life quality, and personal concern. In
particular, RM is extremely stressful [2]. It is, therefore, very
important to conduct research in this area. For women with
RM, there is currently no scientifically evidence-based treat-
ment, which significant could improve their ability to give
live birth. In a Cochrane systematic review on treatment of
women with RM with antiphospholipid antibodies or lupus
anticoagulant, it was concluded that although the combined
treatment with heparin and low dose aspirin may reduce
miscarriage rate in the patients, the quality of the trials was
high due to lack of allocation concealment; furthermore,
the participant characteristics varied very much between
the trials [41].
At least eight randomised placebo-controlled trials
investigating IvIg with a total of 324 RM patients have
been published, with conflicting results [12,17-23].
These differences could in theory be explained by the
fact that the trials conducted until now have been very
heterogeneous with regard to the selection of patients,
doses of IvIg provided and starting time of infusions.
The latest systematic Cochrane review on the topic was
conducted in 2006 and included data from seven placebo-
controlled trials [11]. The review concluded that there was
no significant treatment effect. However it should be noted
that no subgroup analyses were implemented. The treat-
ment is very expensive and could imply potential SAEs. It
is, therefore, very important to detect the relevant patient
group for this treatment if it exists.We will, in our systematic review, include data from
the newest randomised placebo-controlled trial, which
we expect will be published in 2014. We will also in-
clude IPD in our analyses. This would make it possible
to carry out important subgroup analyses with the aim
of evaluating in which subgroup the treatment might
have the highest impact. There is according to our
knowledge no published systematic review on the topic
which has used IPD in the analyses.
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